Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)
Others
Ratios

BioLineRx (BLRX) Cost of Revenue (2023 - 2025)

Historic Cost of Revenue for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $84000.0.

  • BioLineRx's Cost of Revenue fell 8978.1% to $84000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 15844.74%. This contributed to the annual value of $9.3 million for FY2024, which is 15089.38% up from last year.
  • BioLineRx's Cost of Revenue amounted to $84000.0 in Q3 2025, which was down 8978.1% from $72000.0 recorded in Q2 2025.
  • Over the past 5 years, BioLineRx's Cost of Revenue peaked at $8.1 million during Q3 2023, and registered a low of -$13.9 million during Q4 2023.
  • For the 3-year period, BioLineRx's Cost of Revenue averaged around $1.2 million, with its median value being $897000.0 (2024).
  • As far as peak fluctuations go, BioLineRx's Cost of Revenue surged by 14375.22% in 2024, and later crashed by 9766.32% in 2025.
  • Quarter analysis of 3 years shows BioLineRx's Cost of Revenue stood at -$13.9 million in 2023, then skyrocketed by 143.75% to $6.1 million in 2024, then plummeted by 98.62% to $84000.0 in 2025.
  • Its Cost of Revenue stands at $84000.0 for Q3 2025, versus $72000.0 for Q2 2025 and $34000.0 for Q1 2025.